<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03130946</url>
  </required_header>
  <id_info>
    <org_study_id>Axbiopsy</org_study_id>
    <nct_id>NCT03130946</nct_id>
  </id_info>
  <brief_title>Comparison of Two Types of Biopsy in Suspicious Axillary Lymph Nodes</brief_title>
  <official_title>Comparison of the Accuracy and Safety of Biopsy in Suspicious Axillary Lymph Nodes With a Crypo-assisted Stick Freeze Biopsy Device or Fine Needle Aspiration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Axillary lymph node status is a vital prognostic factor in breast cancer patients and
      provides crucial information for making treatment decisions. Ultrasound test with subsequent
      fine needle aspiration (FNA) biopsy in nodes with suspicious features remains the standard of
      axillary lymph node workup. Insufficient sampling and limited diagnostic accuracy of
      cytological test compromise the outcome the preoperative lymph node staging strategy
      especially in patients with intermediate suspicious nodes. This prospective study is to
      compare the performance of a crpo-assisted core biopsy with FNA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective study was planned to evaluate the superiority of a core needle biopsy device
      with a special cryo-assisted rotational design (Cassi II, USA) compared with FNA for biopsy
      of intermediately suspicious lymph nodes. Eligible patients would be randomized to one of two
      arms by 1:2 : Core with FNA or FNA alone. The diagnostic accuracy and adverse outcome of core
      and FNA would be compared.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2017</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two arm, prospective, open label study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of biopsy</measure>
    <time_frame>Immediate after pathological lymph node stage is available</time_frame>
    <description>True positive rate measures the proportion of positives that are correctly identified by Core needle or FNA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Specificity</measure>
    <time_frame>Immediate after pathological lymph node stage is available.</time_frame>
    <description>The true negative rate measures the proportion of negatives that are correctly identified.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sample adequency</measure>
    <time_frame>Immediate after biopsy specimen is evaluated by pathologists.</time_frame>
    <description>The specimen amount or quality for diagnosis is adequate or not evaluated by pathologists</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effect of surgery</measure>
    <time_frame>4 weeks after surgery.</time_frame>
    <description>Hematoma, bleeding need , suture exposure and extrusion.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Cryo-assisted core needle biopsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients undergo lymph node biopsy with FNA and crpo-assisted stick freeze device sequentially.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fine needle aspiration alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo lymph node biopsy with FNA alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cryo-assisted core needle biopsy</intervention_name>
    <description>Rotational core needle biopsy would be done under local anesthesia. A small incision would be made in the axilla and core needle biopsy be performed using a special cryo-assisted stick freeze device (Cassi II, Scion Medical Technologies, USA). The cytological and histological specimens would be sent for diagnosis.</description>
    <arm_group_label>Cryo-assisted core needle biopsy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FNA</intervention_name>
    <description>FNA would be performed using a 10ml syringe with a 24 gauge needle without anesthesia.</description>
    <arm_group_label>Cryo-assisted core needle biopsy</arm_group_label>
    <arm_group_label>Fine needle aspiration alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed invasive breast cancer.

          -  With axillary lymph node with thickened cortex.

          -  Planned for sentinel lymph node biopsy or axillary clearance.

        Exclusion Criteria:

          -  Nodes ultrasonographically normal.

          -  Nodes with hilar displacement .

          -  Palpable matted nodes.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Houpu Yang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Houpu Yang, MD</last_name>
    <phone>88324010</phone>
    <email>yanghoupu@pkuph.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>10044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Houpu Yang, MD</last_name>
      <phone>010-88324010</phone>
      <email>yanghoupu@pkuph.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Houpu Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2017</study_first_submitted>
  <study_first_submitted_qc>April 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2017</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Houpu Yang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>breast neoplasms</keyword>
  <keyword>Ultrasonography, Interventional</keyword>
  <keyword>Biopsy, Large-Core Needle</keyword>
  <keyword>Biopsy, Fine-Needle</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

